Natera, Inc. (NTRA)
NASDAQ: NTRA · IEX Real-Time Price · USD
109.51
+2.00 (1.86%)
May 24, 2024, 4:00 PM EDT - Market closed

Company Description

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide.

Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test.

In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests.

The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners.

It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays.

The company was founded in 2003 and is headquartered in Austin, Texas.

Natera, Inc.
Natera logo
Country United States
Founded 2003
IPO Date Jul 2, 2015
Industry Diagnostics & Research
Sector Healthcare
Employees 3,293
CEO Steven Leonard Chapman

Contact Details

Address:
13011 Mccallen Pass, Building A Suite 100
Austin, Texas 78753
United States
Phone 650-249-9090
Website natera.com

Stock Details

Ticker Symbol NTRA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001604821
CUSIP Number 632307104
ISIN Number US6323071042
Employer ID 01-0894487
SIC Code 8071

Key Executives

Name Position
Dr. Matthew Rabinowitz Ph.D. Co-Founder and Executive Chairman
Steven Leonard Chapman Chief Executive Officer and Director
Michael B. Brophy M.B.A. Chief Financial Officer
Daniel Rabinowitz L.L.M. Secretary and Chief Legal Officer
John Fesko President and Chief Business Officer
Jonathan Sheena M.Eng. Co-Founder and Director
Olesya A. Anisimova CPA Chief Accounting Officer
Rishi Kacker Chief Technology Officer
Eric A. Evans Chief Scientific Officer
Jerry Diffley Chief Compliance and Privacy Officer

Latest SEC Filings

Date Type Title
May 20, 2024 144 Filing
May 15, 2024 144 Filing
May 10, 2024 144 Filing
May 10, 2024 10-Q Quarterly Report
May 9, 2024 8-K Current Report
May 1, 2024 144 Filing
Apr 24, 2024 ARS Filing
Apr 24, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 24, 2024 DEF 14A Other definitive proxy statements
Apr 24, 2024 144 Filing